DBV Technologies upgraded by Societe Generale
$DBVT
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Societe Generale upgraded DBV Technologies from Hold to Buy
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/29/2025 | $7.25 | Sell | Goldman |
| 1/4/2023 | Hold → Buy | Societe Generale | |
| 12/16/2022 | Neutral → Sell | Goldman | |
| 5/10/2022 | $6.00 → $1.50 | Buy → Neutral | Goldman |
| 12/21/2021 | $8.00 → $5.00 | Market Outperform | JMP Securities |
| 12/21/2021 | $14.00 → $10.00 | Buy | HC Wainwright & Co. |
| 9/14/2021 | Hold → Buy | Societe Generale |